ArticleSpine deformity2025
Effects of intraoperative topical hemostatic agents on chest tube output and thoracic complications following vertebral body tethering.
Article in Spine deformity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lumbar, thoracic, and bilateral vertebral body tethering: do surgical outcomes differ?Spine deformity · 2026Article
- Outcomes of Vertebral Body Tethering in Adolescent Idiopathic Scoliosis: A Prospective, Multicenter Study.JB & JS open accessArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeVertebral body tethering (VBT) is an emerging treatment option for idiopathic scoliosis, but routinely requires intraoperative placement of a chest tube (CT). Topical thrombin and injectable collagen have routinely been used as a hemostatic agent, but data are lacking on its use in VBT. Thus, we aim to investigate the impact of the topical hemostatic use on CT output and duration, and the subsequent rate of clinically-significant hemothorax and effusion after VBT.
methodsRetrospective review was conducted on patients who underwent VBT at a single institution between 2015 and 2024. Patients were grouped to whether they were treated with FDA-approved, topically applied recombinant thrombin and injectable collagen intraoperatively. We hypothesized that there would be fewer thoracic and chest tube complications in the topical hemostatic group based on their 90-day perioperative outcomes.
resultsOut of 190 patients who underwent VBT, 92 received thrombin and injectable collagen intraoperatively while 98 did not. Mean age at surgery was 13 (range 9-17) years. Adjusting for chest tube size and number of instrumented levels, regression analysis showed significant decrease in CT output, CT duration, and the odds of developing clinically significant pleural effusion with the use of intraoperative topical hemostatic agents. Two cases of in-hospital hemothorax were found in the non-topical hemostatic group and none in the group with topical hemostatic.
conclusionsApplying topical thrombin and injectable collagen during surgery decreases CT output and duration following VBT, as well as the odds of developing clinically significant pleural effusion. This may serve as an alternative to the use of 24-h intravenous hemostatic agent such as tranexamic acid. LEVEL OF EVIDENCE: Level III-Retrospective Cohort Study. LEVEL OF EVIDENCE: Level III-Retrospective Cohort Study.
Indexed as
Identifiers
40198543What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.